View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
August 16, 2021

Enlivex to commence Phase IIb trial of cell therapy for Covid-19 ARDS

The trial will assess the safety and efficacy of Allocetra given along with the standard of care in a total of 152 subjects.

Enlivex Therapeutics is to begin a Phase IIb clinical trial of universal, off-the-shelf cell therapy, Allocetra, in severe and critical Covid-19 patients with acute respiratory distressed syndrome (ARDS).

Certain diseases, including solid cancers, sepsis and Covid-19 among others, reprogramme macrophages out of their homeostatic state and cause disease severity.

Allocetra can potentially reprogramme macrophages into their homeostatic state to offer a new immunotherapeutic mechanism of action for life-threatening diseases with unmet medical needs, Enlivex noted.

The Israeli Ministry of Health reviewed Phase II trial data of the therapy and authorised the commencement of its Phase IIb trial.

The company-sponsored, multi-centre, placebo-controlled, randomised and blinded Phase IIb trial will evaluate the safety and efficacy of Allocetra when given with the standard of care therapy.

It will enrol a total of up to 152 subjects at clinical sites in Israel and selected European countries.

The primary goals of the trial are ventilation-free survival and recovery for each of the severe, as well as critical subject sub-populations in the trial.

Furthermore, analysis of long-Covid-19 symptoms will be one of the secondary goals of the trial.

Enlivex had reported positive top-line data from Phase Ib and Phase II investigator-initiated trials of Allocetra in patients with severe and critical Covid-19.

Combined results from the trials showed that the cell therapy was safe and well-tolerated.

No deaths were reported in subjects receiving Allocetra by day 28 of the follow-up period.

In addition, 90.5% of severe/critical subjects had improvement in their condition and were discharged from the hospital after an average of 5.6 days.

Enlivex CEO Oren Hershkovitz and chief scientific officer professor Dror Mevorach said in a joint statement: “We would like to thank the Israeli Ministry of Health for the expedited review and for authorising a Phase IIb clinical trial of Allocetra in Covid-19 patients in severe and critical condition.”

In another development, the US Food and Drug Administration has approved Novatek Pharmaceuticals’ investigational new drug (IND) application to conduct a Phase II trial of its oral drug, TQ Formula, for Covid-19 in the outpatient setting.

TQ Formula is a concentrated enteric-coated Nigella Sativa oil formulation with a high thymoquinone concentration.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU